IL1B and chronic obstructive pulmonary disease: Similarly, PDE4i roflumilast, FDA-approved therapy for severe chronic obstructive pulmonary disease (COPD), reduces IL-1β levels and obtains better clearance than ATT alone in the chronic TB mouse model after 8 weeks posttreatment [161].